BIG 1-98 is a phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor (ER and/or PgR) positive tumours.
Coordinating group: IBCSG
Study design
Start date: March 1998 Closure date: May 2003 Target nr. of patients: 8000 Final accrual: 8028
Reason for closure: reached target accrual; first analysis positive